# Semaglutide: Research Overview — Sublingual Peptides > A literature summary of semaglutide's mechanism, its subcutaneous and oral routes, landmark trial results (STEP, SELECT, FLOW, SUSTAIN-6), and cited safety cautions. A GLP-1 receptor agonist studied by injection and, separately, engineered into a tablet — with two very different bioavailability numbers behind those two routes. ## The short version Semaglutide is the lead compound on this desk and a GLP-1 receptor agonist — a synthetic peptide that mimics the gut hormone glucagon-like peptide-1. It's FDA-approved for type 2 diabetes, chronic weight management, reducing major cardiovascular events in adults with obesity or overweight and established cardiovascular disease, and (since 2025) metabolic dysfunction-associated steatohepatitis (MASH) [15]. Of the three peptides on this desk, it's the only one available in two genuinely different, separately engineered forms: a once-weekly subcutaneous injection and a once-daily oral tablet. The injection is the workhorse: in the STEP 1 trial, once-weekly injected semaglutide produced -14.9% average body-weight change at 68 weeks versus -2.4% with placebo [14]. The oral tablet exists because of a specific absorption-enhancer technology, and even with that engineering its bioavailability is only about 0.4-1% [15] — a number that explains why the tablet comes with strict fasted-dosing rules the injection doesn't need. This page covers what's actually documented for each route; it recommends no dose to anyone. ## What it is Semaglutide is a 31-amino-acid synthetic analog of human GLP-1, sharing about 94% sequence identity with the native hormone. Two substitutions give it protease resistance: alanine at position 8 is swapped for alpha-aminoisobutyric acid, blocking the enzyme (DPP-4) that would otherwise break it down in about two minutes, and lysine at position 34 is swapped for arginine. A C18 fatty di-acid chain attached at position 26 drives strong, reversible binding to albumin in the blood, which shields the peptide from clearance and gives it a roughly one-week circulating half-life — the structural basis for once-weekly injection. The oral tablet is a completely separate engineering problem. It's co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), an absorption enhancer that briefly raises the pH of a small patch of stomach lining and lets some of the peptide cross into circulation before acid degrades it. Even with SNAC doing its job, oral bioavailability comes out to only about 0.4-1%, which is why the tablet has to be taken on a genuinely empty stomach with a small sip of water [15]. ## How it works Once in circulation — by either route — semaglutide activates the GLP-1 receptor throughout the body. In the pancreas it boosts glucose-dependent insulin release and suppresses inappropriate glucagon release, meaning it works mainly when blood sugar is already elevated, which limits hypoglycemia risk when used alone. It slows gastric emptying, blunting post-meal glucose spikes and contributing to nausea as a side effect. Its weight effect is mostly central. In rodent studies, semaglutide accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus — reducing food intake and shifting food preference without lowering energy expenditure [16]. Route doesn't change what happens once the peptide reaches these receptors; it changes how much peptide gets there in the first place, and how reliably. ## What the research shows *Head-to-head against tirzepatide.* In the SURMOUNT-5 trial (n=751, injected semaglutide vs injected tirzepatide, both at maximum tolerated dose), tirzepatide produced greater weight loss than semaglutide over 72 weeks (-20.2% vs -13.7%, P<0.001) [11]. *Kidney outcomes (FLOW).* In 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly injected semaglutide reduced major kidney-disease events versus placebo (HR 0.76; 95% CI 0.66-0.88) — a 24% lower risk [12]. *Cardiovascular outcomes (SELECT).* In 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, injected semaglutide reduced major adverse cardiovascular events versus placebo (HR 0.80; 95% CI 0.72-0.90, P<0.001) [13]. *Weight management (STEP 1).* In 1,961 adults with overweight or obesity and no diabetes, injected semaglutide 2.4 mg produced -14.9% mean body-weight change at 68 weeks versus -2.4% with placebo [14]. *Safety profile across routes.* A dedicated review characterizes semaglutide's risk-benefit balance as favorable overall, dominated by mild-to-moderate transient gastrointestinal effects, an increased biliary-disease (gallstone) risk, and unconfirmed pancreatic/thyroid-cancer signals given low incidence — and notes the oral tablet's ~0.4-1% bioavailability and strict fasted-administration requirement [15]. *Central nervous system mechanism (rodent).* Semaglutide lowered body weight in mice and rats by acting on distributed brain circuits — brainstem, area postrema, arcuate nucleus, and parabrachial nucleus — reducing intake and changing food preference without lowering energy expenditure [16]. *Cardiovascular outcomes in diabetes with a retinopathy signal (SUSTAIN-6).* In 3,297 adults with type 2 diabetes at high cardiovascular risk, injected semaglutide reduced major cardiovascular events (HR 0.74; 95% CI 0.58-0.95) but showed a higher rate of diabetic-retinopathy complications (HR 1.76; 95% CI 1.11-2.78) [17]. Every large outcomes trial behind semaglutide — SURMOUNT-5, FLOW, SELECT, STEP 1, SUSTAIN-6 — used the injectable form. The oral tablet's evidence base is comparatively thinner and centers on bioavailability and administration requirements rather than head-to-head outcomes data [15]. ## Reported effects, cautions & safety People using semaglutide describe a fairly consistent set of effects across both injected and oral users — **anecdotal, not clinical evidence**, and none of it substitutes for the trial data above. *Reported benefits:* The most consistently described effect is a quieting of "food noise" — reduced background preoccupation with eating — alongside sharply reduced cravings for sugar and fried food, and steady weight loss over months. People with type 2 diabetes commonly report better blood-sugar readings. A widely discussed secondary effect is reduced interest in alcohol. *Reported adverse effects:* Nausea is the dominant complaint, mentioned by roughly a third of reviewers and usually peaking after dose increases before easing. Sulfur-smelling burps, alternating constipation and diarrhea, acid reflux, injection-day fatigue, and occasional headaches are common. A subset report hair shedding tied to the pace of weight loss rather than the drug itself. *Cited cautions from the literature:* - **Gastrointestinal intolerance during dose escalation** is the leading adverse effect and the main reason people stop — it's dose-related and mostly transient [15]. - **Medullary thyroid carcinoma / MEN-2 is a boxed warning** based on rodent data; the human signal isn't established, but a personal or family history is treated as a contraindication [15]. - **Acute pancreatitis** is a class warning, though quantifying the risk is limited by low incidence [15]. - **Gallbladder and biliary disease risk is increased**, attributed mainly to the pace of weight loss [15]. - **Diabetic retinopathy can worsen with rapid glycemic correction** — SUSTAIN-6 found significantly more retinopathy complications in patients with pre-existing retinopathy [17][15]. - **A meaningful share of weight lost is lean mass**, raising sarcopenia concerns, particularly in older adults [15]. - **Weight regain after stopping is substantial** — about 11.6 percentage points within a year in trial follow-up [15]. - **The oral tablet demands strict fasted dosing** — even a normal amount of water, food, or another oral medicine too soon after the tablet meaningfully cuts absorption [15]. ## Where it fits in delivery-route research Semaglutide is the control case for this entire desk: the only compound here with a genuine, separately engineered, separately measured oral route sitting alongside its injectable form [15]. That the tablet still only reaches ~0.4-1% bioavailability, and needs a strict fasting protocol to get there, says something about how hard the oral-peptide problem actually is — even with a purpose-built absorption enhancer and a large development program behind it. [BPC-157](/bpc-157) and [CJC-1295](/cjc-1295) have no comparable oral engineering at all; what's marketed as oral or sublingual versions of those two rests on no published human absorption data. See the [comparison page](/compare) for all three side by side. ![Semaglutide research illustration — abstract cool scientific motif in midnight gold and blue](/images/semaglutide.webp) --- Sublingual Peptides tracks what's verified route by route — injectable, oral, sublingual — and says plainly when the human data simply isn't there; not a pharmacy, not a supplier, no doses recommended to anyone.